Viridian Therapeutics (VRDN) Set to Announce Quarterly Earnings on Monday

Viridian Therapeutics (NASDAQ:VRDNGet Rating) is scheduled to be announcing its earnings results before the market opens on Monday, November 14th. Analysts expect the company to announce earnings of ($0.87) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

Viridian Therapeutics (NASDAQ:VRDNGet Rating) last announced its earnings results on Monday, August 15th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.20). The company had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.70 million. Viridian Therapeutics had a negative net margin of 10,981.32% and a negative return on equity of 206.72%. During the same quarter in the previous year, the business posted ($2.21) earnings per share. On average, analysts expect Viridian Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Viridian Therapeutics Stock Performance

Shares of NASDAQ:VRDN opened at $20.51 on Friday. The company has a market cap of $583.80 million, a P/E ratio of -4.39 and a beta of 0.84. The company has a debt-to-equity ratio of 0.12, a quick ratio of 7.77 and a current ratio of 7.77. Viridian Therapeutics has a one year low of $9.47 and a one year high of $26.22. The business’s 50-day simple moving average is $20.52 and its 200 day simple moving average is $16.30.

Insiders Place Their Bets

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 425,531 shares of the company’s stock in a transaction on Wednesday, August 17th. The shares were bought at an average cost of $23.50 per share, for a total transaction of $9,999,978.50. Following the acquisition, the director now directly owns 1,363,764 shares of the company’s stock, valued at $32,048,454. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Legal & General Group Plc acquired a new position in shares of Viridian Therapeutics in the 2nd quarter worth approximately $94,000. Royal Bank of Canada acquired a new position in shares of Viridian Therapeutics in the 1st quarter worth approximately $128,000. American International Group Inc. acquired a new position in shares of Viridian Therapeutics in the 2nd quarter worth approximately $140,000. Credit Suisse AG acquired a new position in shares of Viridian Therapeutics in the 2nd quarter worth approximately $206,000. Finally, PDT Partners LLC grew its position in shares of Viridian Therapeutics by 14.1% in the 1st quarter. PDT Partners LLC now owns 14,390 shares of the company’s stock worth $266,000 after acquiring an additional 1,775 shares in the last quarter.

Analysts Set New Price Targets

Several equities research analysts recently commented on VRDN shares. LADENBURG THALM/SH SH raised their target price on Viridian Therapeutics from $33.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 16th. SVB Leerink raised their target price on Viridian Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Monday, August 15th. B. Riley lifted their price objective on Viridian Therapeutics from $25.00 to $40.00 in a report on Tuesday, August 16th. Finally, Evercore ISI lifted their price objective on Viridian Therapeutics from $40.00 to $50.00 in a report on Monday, August 15th.

About Viridian Therapeutics

(Get Rating)

Viridian Therapeutics, Inc, a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED.

Further Reading

Earnings History for Viridian Therapeutics (NASDAQ:VRDN)

Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.